{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:21:57Z","timestamp":1791411717116,"version":"4.3.3"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004605","name":"Zhengzhou University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.pnpbp.2024.111128","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T22:29:09Z","timestamp":1724365749000},"page":"111128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Movement disorders related to antidiabetic medications: a real-world pharmacovigilance study"],"prefix":"10.1016","volume":"135","author":[{"given":"Yingjie","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtao","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2024.111128_bb0005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pnpbp.2013.10.014","article-title":"Novel action of metformin in the prevention of haloperidol-induced catalepsy in mice: Potential in the treatment of Parkinson\u2019s disease?","volume":"48","author":"Adedeji","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0010","first-page":"4757","article-title":"Potential mechanisms of metformin-induced memory impairment","volume":"25","author":"Alhowail","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0015","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2015-3754","article-title":"Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study","volume":"101","author":"Aroda","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/jama.1961.03040120016004","article-title":"A survey of drug-induced extrapyramidal reactions","volume":"175","author":"Ayd","year":"1961","journal-title":"Jama"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0025","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0030","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2337\/diacare.27.5.1023","article-title":"A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70\/30) in patients with type 2 diabetes","volume":"27","author":"Bretzel","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2024.111128_bb0035","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S1353-8020(13)70027-0","article-title":"Acute and subacute drug-induced movement disorders","volume":"20","author":"Burkhard","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/picr.PICR_140_16","article-title":"An evaluation of the impact of antidiabetic medication on treatment satisfaction and quality of life in patients of diabetes mellitus","volume":"9","author":"Chaturvedi","year":"2018","journal-title":"Perspect. Clin. Res."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fendo.2017.00006","article-title":"Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management","volume":"8","author":"Chaudhury","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0050","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/pcn.12405","article-title":"Metformin-induced acute dystonia in a schizophrenic patient treated with sulpiride and clozapine","volume":"70","author":"Chen","year":"2016","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0055","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1080\/14656566.2023.2271389","article-title":"Exploring the nexus of binge eating disorder (BED), New Psychoactive Substances (NPS), and misuse of pharmaceuticals: charting a path forward","volume":"24","author":"Chiappini","year":"2023","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ph16070994","article-title":"Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration\u2019s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset","volume":"16","author":"Chiappini","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0065","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/mds.28551","article-title":"Type 2 Diabetes as a Determinant of Parkinson\u2019s Disease Risk and Progression","volume":"36","author":"Chohan","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/mds.29298","article-title":"Type 2 Diabetes and Parkinson\u2019s Disease: A Focused Review of Current Concepts","volume":"38","author":"Cullinane","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/JPD-171296","article-title":"Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson\u2019s Disease","volume":"8","author":"Curry","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0080","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1474-4422(19)30152-8","article-title":"Recent developments in drug-induced movement disorders: a mixed picture","volume":"18","author":"Factor","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106114","article-title":"Mitochondria as an important target of metformin: The mechanism of action, toxic and side effects, and new therapeutic applications","volume":"177","author":"Feng","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0090","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse Effects of GLP-1 Receptor Agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev. Diabet. Stud."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0095","doi-asserted-by":"crossref","unstructured":"Goldman SA (1998) Limitations and strengths of spontaneous reports data. Clin Ther 20 Suppl C:C40-44.","DOI":"10.1016\/S0149-2918(98)80007-6"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euroneuro.2024.02.003","article-title":"Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis","volume":"82","author":"Guirguis","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0105","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","article-title":"Adverse effects and safety of SGLT-2 inhibitors","volume":"40","author":"Halimi","year":"2014","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0115","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4239\/wjd.v12.i7.916","article-title":"Long-term metformin therapy and vitamin B12 deficiency: An association to bear in mind","volume":"12","author":"Infante","year":"2021","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0120","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1007\/s00018-012-1025-2","article-title":"Energy dysfunction in Huntington\u2019s disease: insights from PGC-1\u03b1, AMPK, and CKB","volume":"69","author":"Ju","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0125","first-page":"194","article-title":"Metformin-induced paroxysmal dystonia","volume":"13","author":"Koc","year":"2008","journal-title":"Neurosciences (Riyadh)"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WAD.0000000000000202","article-title":"Effects of the Insulin Sensitizer Metformin in Alzheimer\u2019s disease: Pilot Data From a Randomized Placebo-controlled Crossover Study","volume":"31","author":"Koenig","year":"2017","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105605","article-title":"Upregulated hexokinase 2 expression induces the apoptosis of dopaminergic neurons by promoting lactate production in Parkinson\u2019s disease","volume":"163","author":"Li","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0140","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202215851","article-title":"Mitochondrial HSF1 triggers mitochondrial dysfunction and neurodegeneration in Huntington\u2019s disease","volume":"14","author":"Liu","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11598540-000000000-00000","article-title":"Drug-induced parkinsonism in the elderly: incidence, management and prevention","volume":"29","author":"L\u00f3pez-Send\u00f3n","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0150","series-title":"IDF diabetes atlas","author":"Magliano","year":"2021"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0155","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199801223380415","article-title":"Lactic acidosis in patients with diabetes treated with metformin","volume":"338","author":"Misbin","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0160","doi-asserted-by":"crossref","first-page":"26438","DOI":"10.1073\/pnas.2009838117","article-title":"Metformin rescues Parkinson\u2019s disease phenotypes caused by hyperactive mitochondria","volume":"117","author":"Mor","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0165","doi-asserted-by":"crossref","unstructured":"Mulvaney CA, Duarte GS, Handley J, Evans DJ, Menon S, Wyse R, Emsley HC (2020) GLP-1 receptor agonists for Parkinson's disease. Cochrane Database Syst. Rev. 7:Cd012990.","DOI":"10.1002\/14651858.CD012990.pub2"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jamadermatol.2020.3385","article-title":"Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride","volume":"157","author":"Nguyen","year":"2021","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0175","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/cc7137","article-title":"Metformin-associated lactic acidosis in an intensive care unit","volume":"12","author":"Peters","year":"2008","journal-title":"Crit. Care"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.678649","article-title":"Association Between Diabetes Medications and the Risk of Parkinson\u2019s Disease: A Systematic Review and Meta-Analysis","volume":"12","author":"Qin","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0185","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-0038-1677050","article-title":"Movement Disorders Emergencies","volume":"39","author":"Rajan","year":"2019","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: An in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0195","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2165\/00003495-200464170-00013","article-title":"Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus","volume":"64","author":"Reynolds","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0200","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/dc19-0760","article-title":"Association Between Glycemic Status and the Risk of Parkinson\u2019s disease: A Nationwide Population-Based Study","volume":"43","author":"Rhee","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0205","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/clinpract13040087","article-title":"Overview of Movement Disorders Secondary to Drugs","volume":"13","author":"Rissardo","year":"2023","journal-title":"Clin Pract"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0210","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nbd.2017.04.004","article-title":"Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson\u2019s disease","volume":"109","author":"Rocha","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0215","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0220","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.molmed.2023.09.005","article-title":"Diabetes: a tipping point in neurodegenerative diseases","volume":"29","author":"Santiago","year":"2023","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0225","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0230","article-title":"Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"381","author":"Shi","year":"2023","journal-title":"Bmj"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0235","doi-asserted-by":"crossref","DOI":"10.4088\/PCC.18l02308","article-title":"Alcohol Dependence, Hypoglycemia, and Transient Movement Disorders","volume":"21","author":"Shukla","year":"2019","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0240","doi-asserted-by":"crossref","first-page":"840","DOI":"10.5114\/aoms.2015.53304","article-title":"Sulfonylureas and their use in clinical practice","volume":"11","author":"Sola","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0245","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1345\/aph.1D468","article-title":"Toxic effects from metformin exposure","volume":"38","author":"Spiller","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0250","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/dom.13826","article-title":"Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial","volume":"21","author":"Tack","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0255","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1212\/WNL.0000000000200771","article-title":"Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer\u2019s disease Risk: A Mendelian Randomization Study","volume":"99","author":"Tang","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155223","article-title":"Metformin: Is it a drug for all reasons and diseases?","volume":"133","author":"Triggle","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0265","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1007\/s10072-023-06965-9","article-title":"Do oral antidiabetic medications alter the risk of Parkinson\u2019s disease? An updated systematic review and meta-analysis","volume":"44","author":"Xie","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0270","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s13238-021-00858-3","article-title":"Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer\u2019s disease mouse model","volume":"12","author":"Xu","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0275","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1038\/s41598-021-81349-7","article-title":"Inhibition of mitochondrial function by metformin increases glucose uptake, glycolysis and GDF-15 release from intestinal cells","volume":"11","author":"Yang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2024.111128_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104803","article-title":"Efficacy of metformin targets on cardiometabolic health in the general population and non-diabetic individuals: a Mendelian randomization study","volume":"96","author":"Zheng","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pnpbp.2024.111128_bb0285","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1186\/s12967-023-04565-x","article-title":"Genetically proxied antidiabetic drugs targets and stroke risk","volume":"21","author":"Zhu","year":"2023","journal-title":"J. Transl. Med."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584624001969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584624001969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T01:01:26Z","timestamp":1726275686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584624001969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":56,"alternative-id":["S0278584624001969"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2024.111128","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Movement disorders related to antidiabetic medications: a real-world pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2024.111128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111128"}}